Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma, as assessed by evaluating the change in pituitary tumor volume at Week 48 (after 12 injection – V5) compared to baseline volume (V1). A 20% reduction from baseline (as measured by MRI at V1) will be considered to be clinically significant.
Critère d'inclusion
- ACROMEGALY ASSOCIATED WITH PITUITARY GLAND MACROADENOMA